Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer

Journal of Urology

Volumn 187, Issue 4, 2012, Pages 1458-1465

  Hadaschik, Boris ^a   Su, Yun ^a,c   Huter, Eva ^a   Ge, Yingzi ^b   Hohenfellner, Markus ^a   Beckhove, Philipp ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

antigens; immunotherapy; prostate; prostatic neoplasms; T lymphocytes, regulatory

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; MELANOMA ANTIGEN 3; MUCIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SURVIVIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER STAGING; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC ACID PHOSPHATASE 3; PROSTATIC ACID PHOSPHATASE 5; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELLS, CULTURED; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84858699653     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.11.083     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. W.K. Oh, P.W. Kantoff Management of hormone refractory prostate cancer: current standards and future prospects J Urol 160 1998 1220
3. L. Matera The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer Cancer Treat Rev 36 2010 131
4. A.L. Harzstark, E.J. Small Immunotherapeutics in development for prostate cancer Oncologist 14 2009 391
5. X. Wang, J. Yu, A. Sreekumar Autoantibody signatures in prostate cancer N Engl J Med 353 2005 1224
6. E.M. Tan, J. Zhang Autoantibodies to tumor-associated antigens: reporters from the immune system Immunol Rev 222 2008 328
7. M. Mercader, B.K. Bodner, M.T. Moser T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A 98 2001 14565
8. M.G. Sanda, D.C. Smith, L.G. Charles Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer Urology 53 1999 260
9. J. Vieweg, Z. Su, P. Dahm Reversal of tumor-mediated immunosuppression Clin Cancer Res 13 2007 727s
10. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
11. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099
12. E.M. Shevach Fatal attraction: tumors beckon regulatory T cells Nat Med 10 2004 900
13. A.M. Miller, K. Lundberg, V. Ozenci CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients J Immunol 177 2006 7398
14. J. Yokokawa, V. Cereda, C. Remondo Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer Clin Cancer Res 14 2008 1032
15. M. Vergati, V. Cereda, R.A. Madan Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination Cancer Immunol Immunother 60 2011 197
16. A.V. D'Amico, R. Whittington, S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
17. M. Feuerer, P. Beckhove, L. Bai Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow Nat Med 7 2001 452
18. A. Bonertz, J. Weitz, D.H. Pietsch Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma J Clin Invest 119 2009 3311
19. M.V. Peshwa, J.D. Shi, C. Ruegg Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide Prostate 36 1998 129
20. A. Machlenkin, R. Azriel-Rosenfeld, I. Volovitz Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice Cancer Immunol Immunother 56 2007 217
21. B.H. Xue, Y. Zhang, J.A. Sosman Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen Prostate 30 1997 73
22. P. Correale, K. Walmsley, C. Nieroda In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen J Natl Cancer Inst 89 1997 293
23. C.J. Melief, S.H. van derBurg Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat Rev Cancer 8 2008 351
24. C.G. Drake Prostate cancer as a model for tumour immunotherapy Nat Rev Immunol 10 2010 580
25. N.C. Di Paolo, S. Tuve, S. Ni Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses Cancer Res 66 2006 960
26. M.L. Salem, A.N. Kadima, S.A. El-Naggar Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells J Immunother 30 2007 40
27. J. Dannull, Z. Su, D. Rizzieri Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 2005 3623
28. C.J. Melief Cancer immunotherapy by dendritic cells Immunity 29 2008 372
29. E.J. Akins, M.L. Moore, S. Tang In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice Cancer Res 70 2010 3473
30. M.S. Arredouani, S.S. Tseng-Rogenski, B.K. Hollenbeck Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice Prostate 70 2010 1002